• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Opioid maker Insys to pay $225M to settle fraud charges

cafead

Administrator
Staff member
  • cafead   Jun 06, 2019 at 12:32: PM
via In early 2013, a physician's assistant practicing at a pain clinic in a small New Hampshire city joined a speaker program run by Insys Therapeutics, the maker of the fentanyl spray Subsys. The assistant then went on to write 672 Subsys prescriptions, despite having never prescribed the drug in the 16 months prior.

The speaker's program was a sham, according to charges brought by the U.S. government against Insys, used by the drugmaker as a "vehicle to pay bribes and kickbacks" to practitioners for prescribing more of the potent opioid painkiller.

article source